These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 22588067)
1. Podoplanin lymphatic density and invasion correlate with adverse clinicopathologic and biological factors and survival in neuroblastomas. Ramani P; Somerville MS; May MT Am J Surg Pathol; 2012 Jun; 36(6):908-15. PubMed ID: 22588067 [TBL] [Abstract][Full Text] [Related]
2. PROX1 lymphatic density correlates with adverse clinicopathological factors, lymph node metastases and survival in neuroblastomas. Ramani P; Norton A; Somerville MS; May MT J Neurooncol; 2012 Jul; 108(3):375-83. PubMed ID: 22382784 [TBL] [Abstract][Full Text] [Related]
3. LYVE-1 upregulation and lymphatic invasion correlate with adverse prognostic factors and lymph node metastasis in neuroblastoma. Ramani P; Dungwa JV; May MT Virchows Arch; 2012 Feb; 460(2):183-91. PubMed ID: 22241180 [TBL] [Abstract][Full Text] [Related]
4. VEGF-C, VEGF-D and VEGFR-3 expression in peripheral neuroblastic tumours. Ramani P; Nash R; Radevsky L; Patel A; Luckett M; Rogers C Histopathology; 2012 Dec; 61(6):1006-16. PubMed ID: 22804730 [TBL] [Abstract][Full Text] [Related]
5. Angiogenin up-regulation correlates with adverse clinicopathological and biological factors, increased microvascular density and poor patient outcome in neuroblastomas. Dungwa JV; Uparkar U; May MT; Ramani P Histopathology; 2012 May; 60(6):911-23. PubMed ID: 22372545 [TBL] [Abstract][Full Text] [Related]
6. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206 [TBL] [Abstract][Full Text] [Related]
7. High levels of polo-like kinase 1 and phosphorylated translationally controlled tumor protein indicate poor prognosis in neuroblastomas. Ramani P; Nash R; Sowa-Avugrah E; Rogers C J Neurooncol; 2015 Oct; 125(1):103-11. PubMed ID: 26318737 [TBL] [Abstract][Full Text] [Related]
8. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index. Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714 [TBL] [Abstract][Full Text] [Related]
9. High incidence of MYCN amplification in a Moroccan series of neuroblastic tumors: comparison to current biological data. Tabyaoui I; Tahiri-Jouti N; Serhier Z; El Maani K; Cherkaoui S; Al Zemmouri M; Othmani MB; Zamiati S Diagn Mol Pathol; 2013 Jun; 22(2):112-8. PubMed ID: 23628823 [TBL] [Abstract][Full Text] [Related]
10. Copy number gain of MYCN gene is a recurrent genetic aberration and favorable prognostic factor in Chinese pediatric neuroblastoma patients. Wang M; Zhou C; Cai R; Li Y; Gong L Diagn Pathol; 2013 Jan; 8():5. PubMed ID: 23320395 [TBL] [Abstract][Full Text] [Related]
11. GLUT1 protein expression correlates with unfavourable histologic category and high risk in patients with neuroblastic tumours. Ramani P; Headford A; May MT Virchows Arch; 2013 Feb; 462(2):203-9. PubMed ID: 23307190 [TBL] [Abstract][Full Text] [Related]
12. [Pathology of peripheral neuroblastic tumors]. Wang L; He LJ; Shimada H Zhonghua Bing Li Xue Za Zhi; 2012 Apr; 41(4):283-8. PubMed ID: 22800533 [No Abstract] [Full Text] [Related]
13. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. Asgharzadeh S; Pique-Regi R; Sposto R; Wang H; Yang Y; Shimada H; Matthay K; Buckley J; Ortega A; Seeger RC J Natl Cancer Inst; 2006 Sep; 98(17):1193-203. PubMed ID: 16954472 [TBL] [Abstract][Full Text] [Related]
14. MYCN gene amplification in patients with neuroblastic tumors. Estiar MA; Fazilaty H; Aslanabadi S; Seifi M; Varghaei P; Rezamand A Cell Mol Biol (Noisy-le-grand); 2014 Sep; 60(3):23-8. PubMed ID: 25231001 [TBL] [Abstract][Full Text] [Related]
15. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines. Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333 [TBL] [Abstract][Full Text] [Related]
16. [Study on MYCN gene amplification and CD44 expression in neuroblastoma]. Hu HL; He LJ Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318 [TBL] [Abstract][Full Text] [Related]
17. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study. Moreau LA; McGrady P; London WB; Shimada H; Cohn SL; Maris JM; Diller L; Look AT; George RE Clin Cancer Res; 2006 Oct; 12(19):5693-7. PubMed ID: 17020972 [TBL] [Abstract][Full Text] [Related]
18. Dickkopf-3 expression is a marker for neuroblastic tumor maturation and is down-regulated by MYCN. Koppen A; Ait-Aissa R; Koster J; Øra I; Bras J; van Sluis PG; Caron H; Versteeg R; Valentijn LJ Int J Cancer; 2008 Apr; 122(7):1455-64. PubMed ID: 18059033 [TBL] [Abstract][Full Text] [Related]
19. [Prognostic significance of MYCN amplification in children neuroblastic tumors]. Niu H; Xu T; Wang F; Chen Z; Gao Q; Yi P; Xia J Zhonghua Bing Li Xue Za Zhi; 2015 Feb; 44(2):111-7. PubMed ID: 25916642 [TBL] [Abstract][Full Text] [Related]
20. The neuroendocrine and neural profiles of neuroblastomas, ganglioneuroblastomas, and ganglioneuromas. Molenaar WM; Baker DL; Pleasure D; Lee VM; Trojanowski JQ Am J Pathol; 1990 Feb; 136(2):375-82. PubMed ID: 1689542 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]